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Abstract
Background—Some obese adults are not afflicted by the metabolic abnormalities often 
associated with obesity [the “metabolically healthy obese” (MHO)], however, they may be at 
increased risk of developing cardiometabolic abnormalities in the future. Little is known about the 
relative incidence of individual components of metabolic syndrome (MetSyn).
Methods—We used data from a multi-center, community-based cohort aged 45–64 years at 
recruitment [the Atherosclerosis Risk in Communities (ARIC) study] to examine the first 
appearance of any MetSyn component, excluding waist circumference. Body mass index (BMI, 
kg/m2) and cardiometabolic data were collected at four triennial visits. Our analysis included 
3,969 adults who were not underweight and free of the components of MetSyn at the initial visit. 
Participants were classified as metabolically healthy normal weight (MHNW), over weight 
(MHOW) and MHO at each visit. Adjusted hazard ratios (HR) and 95% confidence intervals were 
estimated with proportional hazards regression models.
Results—The relative rate of developing each risk factor was higher among MHO than MHNW 
with the strongest association noted for elevated fasting glucose [MHO vs. MHNW, HR: 2.33 
(1.77, 3.06)]. MHO was also positively associated with elevated triglycerides [HR: 1.63 (1.27, 
2.09)], low HDL-C [HR: 1.68 (1.32, 2.13)] and elevated blood pressure [HR: 1.54 (1.26, 1.88)]. A 
similar, but less pronounced pattern was noted among the MHOW vs. MHNW.
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Conclusions—We conclude that even among apparently healthy individuals, obesity and 
overweight are related to more rapid development of at least 1 cardiometabolic risk factor, and that 
elevations in blood glucose develop most rapidly.
Keywords
metabolically healthy obese; cardiometabolic risk factors; metabolic syndrome
Introduction
Although the association between obesity and markers of chronic disease risk is well 
documented,1 a subgroup of individuals with high BMI have metabolic markers that fall 
within the normal range.2 These so-called metabolically healthy obese (MHO) and 
metabolically healthy overweight (MHOW) exhibit normal blood pressure and lipids, and 
possess a higher degree of insulin sensitivity and glucose control than their unhealthy 
counterparts.3 According to one study2 the metabolically healthy represent over 30% of 
obese [body mass index (BMI) >=30 kg/m2] and over 50% of overweight (BMI >=25 kg/m2 
and <30 kg/m2) U.S. adults. Some researchers have suggested that this subset of obese 
individuals with a favorable metabolic profile exhibits a risk of chronic disease similar to 
those of normal-weight (BMI < 25.0 kg/m2),4, 5 although this observation remains 
controversial.6
While previous work, including one study from our group,7 has shown an increased 
incidence of overt metabolic syndrome among the MHO,7–9 there has been little work 
considering the incidence of individual components of MetSyn among the MHO. Most of 
the previous studies on individual components have been conducted in populations living in 
Asia and the results from these studies may therefore not be broadly generalizable as the 
relationships between body size, body composition, and health outcomes may be different in 
this group compared to other racial/ethnic groups.10 In one cohort of adult Korean men free 
from all metabolic abnormalities, obesity was associated with increased incidence of 
dyslipidemia, pre-hypertension, fatty liver and elevated HOMA-IR.11 Other studies in 
metabolically healthy Asian populations that considered more limited sets of 
cardiometabolic outcomes have reported positive associations of obesity with incident 
hypertension8, 12, 13 and type 2 diabetes.8, 14, 15 Studies in Spain,16, 17 the United States,4, 18 
United Kingdom,19, 20 Australia,21 and Israel,22 have also described an increased risk of 
diabetes among the MHO. The relationship between MHO and dyslipidemia (low high 
density lipoprotein (HDL) and high triglycerides) has been largely unexplored.
To date, we know of no study that has compared the incidence of multiple individual 
cardiometabolic abnormalities between obese and normal weight males and females in U.S. 
populations who were initially free of any component of MetSyn. A comprehensive 
understanding of the evolution of cardiometabolic risk factors, in particular which ones 
develop most rapidly, would provide valuable insight into the course of the metabolically 
healthy obese population as well as suggest which conditions may be sentinel events for 
development of the clustering of these metabolic abnormalities. This would be of interest to 
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clinicians and public health professionals when designing and implementing primary 
prevention efforts in this population.
The primary objective of our current study is to compare the incidence of cardiometabolic 
abnormalities between the metabolically healthy normal weight (MHNW), MHOW, and 
MHO using data from a community-based cohort of white and African-American adults. We 
examined the incidence of individual cardiometabolic abnormalities (dyslipidemia, elevated 
blood pressure, glucose dysregulation) as well as the overall incidence of any component. 
We also examined effect modification of these associations by race, age, sex and physical 
activity.
Methods
Study Population
Our analysis used data from the Atherosclerosis Risk in Communities (ARIC) Study, a 
prospective cohort study of the etiology of atherosclerosis in adult white and African-
American men and women. The ARIC study was conducted in four U.S. communities 
(Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; Washington County, 
MD)23 and was approved by the Institutional Review Boards at each site.
Data Collection
The total ARIC study sample included 15,792 men and women aged 45 to 64 years. The first 
visit occurred between 1987 and 1989 with follow-up visits approximately every 3 years 
(1990–1992, 1993–1995 and 1996–1998). Participation rates at the 2nd–4th visits were 93%, 
86% and 81%, respectively. At each visit participants answered interviews administered by 
trained study personnel using standardized questionnaires that assessed sociodemographic 
and lifestyle factors relevant to the etiology of cardiovascular disease. At the first and third 
visits usual diet was assessed using a modification of the 66-item food frequency 
questionnaire developed by Willett,24 while physical activity was assessed using a modified 
version of the Baecke questionnaire.25
Physiological and anthropometric measures were collected in clinic visits. Blood was 
collected from an antecubital vein into a vacuum tube with ethylenediamine tetraacetic acid 
(for lipids) or a serum separator gel (for glucose). Triglycerides, high density lipoprotein 
(HDL) and serum glucose were assayed using enzymatic methods, dextran-magnesium 
precipitation and hexokinase/glucose-6-phosphate dehydrogenase, respectively.23 Three 
blood pressure measurements were obtained using a random-zero sphygmomanometer and 
the last two measurements were averaged. Body weight was measured using a calibrated 
scale with subjects in scrub suits without shoes and height was measured using a ruler.
Outcomes—Outcomes were the incidence of individual components of MetSyn as defined 
by the National Cholesterol Program’s Adult Treatment Panel III (ATP III) guidelines:26 1) 
elevated triglycerides: >=150 mg/dL; 2) low HDL cholesterol, men: <40 mg/dL, women: 
<50 mg/dL; 3) elevated blood pressure: >=130 or >=85 mm Hg; 4) elevated fasting glucose: 
>=110 mg/dL. Additionally, subjects were considered to meet the criteria for each of the 
above listed components if they were taking medications to manage the corresponding 
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condition. Elevated waist circumference (>40 inches for men, >35 inches for women 
according to the ATP III guidelines26) was not considered because most obese individuals, 
and few normal weight individuals, would satisfy this criterion by virtue of body size and so 
it may not be a direct marker of metabolic dysfunction.
Exposure—The exposure for this analysis was body mass index (BMI), defined as the 
ratio of weight in kilograms to squared height in meters using the height at visit 1 and the 
measured weight collected at the four visits. We categorized BMI according to standard 
cutpoints of 18.5–<25.0 (normal weight), 25.0–<30.0 (overweight) and >=30.0 (obese).
Participants were sequentially excluded from the analysis if they had any component of 
MetSyn at visit 1, excluding elevated waist circumference (n=11,046 total; which included 
4,365 with elevated triglycerides, 5,824 with low HDL-C, 7,220 with elevated blood 
pressure, and 3,287 with elevated fasting glucose), were underweight or missing BMI at 
baseline (n=265), missing covariate data (n=51) or had non-fasting blood glucose data at 
visit 1 (n=554). Our final sample included 3,969 subjects who were free from any of the 
previously described cardiometabolic abnormalities, and not taking medications for them, at 
the initial ARIC visit.
Statistical Analysis
Hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI category 
with development of at least one risk factor, and each individual cardiometabolic risk factor, 
were estimated using a Weibull model for interval-censored time-to-event data.27 Interval 
censored methods were used because the outcomes for this analysis were assessed according 
to the ARIC visit schedule and thus the specific dates of onset were unknown. For each of 
the four individual outcomes (elevated triglycerides, low HDL cholesterol, high blood 
pressure, elevated glucose) and for the outcome of any one or more of the above, a dataset 
that included multiple records per subject was created (one observation per subject per 
interval, with a minimum of 1 and a maximum of 3 observations per subject) with a binary 
variable indicating if the outcome had occurred within the corresponding interval or not. 
Subjects were right censored if they did not achieve the outcome by their last observed 
follow-up. For analyses of the individual cardiometabolic risk factors, subjects were also 
censored if they developed any of the other risk factors before the one under consideration as 
this would violate our definition of metabolically healthy for subsequent outcomes. We also 
considered analyses that allowed for recurrent events28 (e.g. individuals who were 
metabolically unhealthy in visit 2, then were healthy again for visit 3 and thus at risk of 
another event by visit 4), but sparsity of the data prevented these models from converging. 
Since the Weibull model was estimated in the accelerated failure time metric we converted 
the parameters to hazard ratios by multiplying the negative of each coefficient by the shape 
parameter and calculated standard errors by the delta method. The primary exposure, BMI 
category at the beginning of each interval, was treated as a time-varying covariate as its 
value was allowed to change at each follow-up visit. All models were adjusted for age 
(continuous), sex (male, female), race (white, African-American), education level (less than 
high school, high school graduate or vocational school, attended college), smoking status 
(never, former, current), alcohol use (never/rare, former, light, medium, heavy) and leisure 
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time physical activity [tertiles of Baecke index25]. Additional adjustment by total caloric 
intake did not materially change the effect estimates and so it was excluded from the final 
models. To assess the trend with respect to continuous BMI and incidence of 1 or more 
MetSyn component we used restricted quadratic splines, linear splines and simple linear 
coding of BMI with the spline knots at the mid- and end-points of the BMI categories 
(22.75, 25.0, 27.5, 30.0 kg/m2); nested models were compared using the likelihood ratio test.
29
 We also plotted the unadjusted cumulative probability of developing at least one MetSyn 
component, which is analogous to an adjusted Kaplan-Meier failure curve for continuous 
time-to-event data. To assess multiplicative interaction by race, age, sex, physical activity 
and BMI at age 25 years we included product terms for BMI category and race group (black, 
white), age group (45–54 years, 55–64 years), sex (male, female), physical activity (tertiles), 
and BMI at age 25 years (≥25 vs. <25; dichotomized to avoid small strata). BMI at 25 years 
was calculated from self-reported recalled weight at age 25 and measured height at visit 1.30 
These were compared to models without the interaction terms using the likelihood ratio test 
with a significance level of 5%. To assess the joint associations of overall body size and 
central adiposity over the follow-up we also report associations of combinations of BMI and 
elevated waist circumference (WC; categorized as ≥102 cm for males, ≥88 cm for females) 
relative to the single reference group with normal weight and normal waist circumference. 
The statistical analysis was performed with the “survival” package31, 32 in R 3.3.1.33
Results
Characteristics of the study sample at visit 1 are shown in Table 1. The number of 
individuals initially considered metabolically healthy was lower in the obese group than the 
normal weight group, with 2,062 individuals in the MHN group at visit 1 and 458 
individuals in the MHO group. The mean age at visit 1 was similar across BMI categories, 
and African-American race was more common among MHOW and MHO individuals. 
Greater education, and greater prevalence of current smoking was somewhat more common 
among MHN individuals. Physical activity levels tended to be higher among the MHN and 
MHOW individuals compared to the MHO. The number of individuals who developed a 
metabolic abnormality by visit 2 but became free from all conditions by visit 3 were: 89 (of 
413) for elevated triglycerides, 180 (of 580) for low HDL-C, 86 (of 557) for elevated BP, 
and 113 (of 432) for elevated fasting glucose (data not in tables). Of these, there were 34 
second episodes (by visit 4) of elevated triglycerides, 59 of low HDL-C, 45 for elevated BP 
and 29 elevated fasting glucose.
As shown in Figure 1, the risk of developing one or more cardiometabolic abnormalities 
over 9 years of follow-up among the MHOW was 23% higher compared to the MHN [HR: 
1.23 (1.11, 1.36)] and 45% higher for the MHO compared to the MHN [HR: 1.45 (1.25, 
1.69)]. In analyses that considered the separate components of MetSyn individually, the 
MHO developed each of the components faster than the MHN individuals. The MHO 
developed elevated triglycerides [HR: 1.63 (1.27, 2.09)], low HDL-C [HR: 1.68 (1.32, 2.13)] 
and high blood pressure [HR: 1.54 (1.26, 1.88)] more than 50% faster than the MHN (Table 
2). The most pronounced effect was observed for elevated glucose, with the rate of 
developing this component in the MHO more than twice that of the MHN [HR: 2.33 (1.77, 
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3.06)]. A less pronounced, although consistent increase in rate of developing these 
components was also observed among the MHOW.
In the trend analysis the linear spline coding was adequate to describe the relationship 
between BMI and any MetSyn component when compared to the restricted quadratic spline 
and simple linear coding. Figure 2 shows the estimated hazard ratios and 95% confidence 
intervals from the linear spline model for an increase in BMI from a reference level of 21.75 
kg/m2 (the midpoint of the normal weight range). Overall the incidence of at least 1 MetSyn 
component increased with increasing BMI across the entire range.
There was no significant effect modification of the association between body size and 
incidence of MetSyn components in the metabolically healthy by age group, sex or BMI at 
age 25 years (all p-values for test of interaction > 0.05; Table 3). We observed significant 
interaction between BMI and race for the rate of developing low HDL-C and elevated fasting 
glucose, with the associations more pronounced among whites than blacks. This was also 
reflected by a significant interaction between BMI and race when considering the incidence 
of at least one cardiometabolic abnormality [black MHOW HR: 1.03 (0.78, 1.35), MHO HR: 
1.08 (0.80, 1.47); white MHOW HR: 1.32 (1.18, 1.47), MHO HR: 1.57 (1.32, 1.87); p-
interaction<0.001 (data not presented in table)]. We also did not observe heterogeneity of the 
relationship of BMI and any incidence of any of the MetSyn components by physical 
activity (all p-values for test of interaction > 0.05; data not shown).
As shown in Table 4, the combination of obesity and elevated waist circumference, 
compared to normal weight and normal waist circumference was most strongly associated 
with increased risk of low HDL-C [HR: 1.77 (1.39, 2.24); p-interaction: 0.03] and high 
blood pressure [HR: 1.57 (1.28, 1.93); p-interaction: 0.02]. Qualitatively, a similar pattern 
was observed for elevated triglycerides [obese/elevated WC vs. normal weight/normal WC, 
HR: 1.68 (1.30, 2.16)] and elevated glucose [obese/elevated WC vs. normal weight/normal 
WC, HR: 2.45 (1.86, 3.23)].
Discussion
In our sample of white and African-American adults free from any component of MetSyn, 
we observed an increase in risk of developing at least one cardiometabolic abnormality over 
9 years of follow-up. There was a consistent increase in the rate of development of MetSyn 
components among the MHO, relative to MHNW, with glucose dysregulation developing the 
most rapidly. The results were largely consistent across age groups, although MHO and 
MHOW females tended to develop these MetSyn components more rapidly than their male 
counterparts.
In a previous analysis in the ARIC cohort we reported that obesity was associated with 4.5 
times the risk of developing incident MetSyn over the 3 follow-up visits.7 However, that 
study focused on MetSyn as a single outcome (attainment of 3 or more of the MetSyn 
characteristics) and so did not consider the effect of body size on individual cardiometabolic 
factors. To our knowledge, this current report is the only study of multiple components of 
metabolic health among the MHO in a United States cohort. The report by Chang et al. is the 
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only other study to comprehensively consider individual components of MetSyn in a manner 
comparable to our analysis, but their study was in a Korean sample and limited to males.11 
The associations that they reported for elevated triglycerides and low HDL-C were similar in 
magnitude to those that we observed among men when we stratified our analysis by sex. 
However, in contrast to our findings, they reported increases in risk of 13% for elevated 
glucose and 85% for elevated blood pressure among the MHO compared to the MHNW11 
which are notably different than the 104% and 29% increases, respectively, that we found 
among males. One factor that may be related to these discrepancies is that the lower end of 
the age range in the Chang study was 15 years less than in the ARIC cohort, and so their 
analysis included more younger men. Additionally, they excluded individuals with evidence 
of fatty liver on ultrasound or elevated homeostasis model assessment-insulin resistance 
(HOMA-IR) and thus may have removed individuals who were more likely to present with 
glucose dysregulation in the short follow-up period. In a recent letter, Bell and colleagues 
describe incidence of individual MetSyn components in the Whitehall II study of British 
adults.20 Although they reported that the MHO were significantly more likely to develop 
insulin resistance, high blood glucose and hypertension over increasingly longer periods of 
follow-up, their classification of MHO status was defined at the baseline visit and thus their 
analysis did not account for individuals changing MHO classification over their follow-up as 
in our present analysis and in the study by Chang et al.11
Most of the other studies of incident metabolic abnormalities focused exclusively on 
incident diabetes, with associations more pronounced than what we report here for elevated 
glucose, with many reporting relative risks between 2 and 4.4, 14–16, 18, 19, 21, 22 The 
strongest association was noted in the study by Hwang et al. in which the MHO had more 
than 11 times the risk of diabetes than MHN subjects.8 All studies that examined elevated 
blood pressure or hypertension among the MHO reported significant increases compared to 
MHN.8, 11–13
A potential difference between our analysis and previous ones, especially those that did not 
examine multiple abnormalities, is that for each outcome we administratively censored those 
who developed any of the other MetSyn components at the event time, as they no longer met 
the criteria for metabolic health in the subsequent follow-up periods. For example, when 
considering hypertension as an outcome, if a subject had developed elevated triglycerides at 
visit 2 while remaining free of hypertension they would have been censored for blood 
pressure at visit 2 (but counted as an event in the triglyceride analysis). These individuals 
may have gone on to subsequently develop additional components (e.g. low HDL-C), but we 
would not have counted the later events. This approach was chosen to maintain a consistent 
definition of metabolic health across all of the follow-up periods. Retaining individuals who 
develop some components of MetSyn would create heterogeneity in the exposed group 
(MHO) across the follow-up. Because MHO are at greater risk of developing each of the 
components of MetSyn, that group would grow less healthy over time, making the 
interpretation of the effect of MHO unclear due to its changing definition.
We did not observe statistically significant effect modification by age, sex, physical activity, 
or BMI at age 25, although there was a more pronounced association between obesity and 
rate of incident low HDL-C and elevated glucose among whites compared to blacks. These 
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differences are consistent with previous observations that at a given BMI white individuals 
carry more visceral adipose tissue than blacks34, 35 and that visceral adiposity may be more 
relevant for identifying individuals in these race groups who are at high risk for developing 
metabolic abnormalities.36 Our results suggest that the etiology of the transition of the MHO 
state to a metabolically unhealthy state may differ by race. Because these different 
cardiometabolic abnormalities may influence specific outcomes differently (e.g. myocardial 
infarction and diabetes), these findings may have implication for identification of subgroups 
of the MHO who are higher risk for particular diseases.
Our findings regarding the relationship between the joint association of BMI and waist 
circumference suggest that body composition may play an important role in the transition 
between healthy to unhealthy status.
Although the clinical and public health utility of understanding obesity phenotypes has been 
discussed previously,3, 37 an unresolved issue is the lack of consensus regarding the 
definition of metabolic health.38, 39 This inconsistency both hinders the clinical application 
of this concept and makes results difficult to interpret across studies.40 The clustering of 
cardiometabolic risk factors that defines MetSyn is believed to be driven by insulin 
resistance41 and so attempts to refine the definition have included direct markers of insulin 
resistance4, 12 and inflammation2, 42 to more precisely characterize a high-risk obese 
phenotype. However, in studies that considered multiple definitions of metabolic health, 
authors have noted that associations are qualitatively similar regardless of the definition. 
Using data from the Framingham Offspring Study, Meigs et al. reported comparable 
associations between obesity phenotypes and the outcomes of type 2 diabetes and 
cardiovascular disease using two different definitions of metabolic health: 1) absence of 
MetSyn (2 or less out of the 5 components) or 2) HOMA-IR below the 75th percentile.4 In a 
Korean population, odds ratios for development of hypertension comparing MHO to MHN 
ranged from 1.46–1.5812 when metabolic health was defined according to the ATP-III 
definition (omitting waist circumference, as we did), the criteria of Wildman et al.2 and 
Karelis et al.42 (both including C-reactive protein), and the HOMA-IR definition used by 
Meigs et al.4 Given the consistency of these associations across these different definitions 
we expect our results to be robust to the classification of metabolic health, however 
refinement of the definition of metabolic health should remain a priority for future research.
Strengths of our study include its relatively large sample size and standardized assessments 
of measured anthropometric characteristics and cardiometabolic outcomes. While these 
strengths are important, our results should be interpreted in light of a few limitations. As 
mentioned previously, research into the MHO phenotype is currently limited by lack of a 
consistent definition of metabolic health.39, 40, 43 This implies some inconsistency in 
defining the target population, and could muddle the interpretation of these findings since 
some marginally unhealthy individuals could be classified as healthy. While the age range of 
the ARIC study corresponds to that for which cardiovascular disease is most relevant, we 
were limited in our ability to investigate these associations among older, or younger 
individuals. Additionally, although 9 years of follow-up is longer than most of the previous 
studies, additional follow-up would allow for more detailed of how these associations may 
change over time. Finally, individuals may transition in and out of unhealthy status 
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becoming repeatedly at risk of metabolic abnormalities, but there were too few second 
events among such individuals in these data to allow us to investigate this, which is a 
common issue in recurrent event analysis.28 Studies of transitory states of metabolic health 
would require longer follow-up than we had available.
In conclusion, among a cohort of adults who were free of the components of MetSyn (except 
waist circumference), we observed that excess weight was associated with more rapid 
development of a cardiometabolic abnormality compared to normal weight individuals. Our 
results add to the evidence that these factors are strongly associated with excess adiposity 
among U.S. adults, even among those who may appear initially free from these conditions. 
Future research should seek to understand the increase in chronic disease risk in this 
subpopulation of obese subjects as well as potential behavioral and lifestyle interventions 
aimed to achieve stable cardiometabolic risk factors.
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Figure 1. 
Unadjusted estimated cumulative probability and adjusted hazard ratios for incidence of 1 or 
more MetSyn component over 4 ARIC visits among metabolically healthy individuals, by 
BMI level. The Atherosclerosis Risk in Communities (ARIC) Study, 1987–1998.
* Hazard ratios adjusted for age, sex, field center, race, alcohol use, smoking, education, 
physical activity.
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Figure 2. 
Adjusted hazard ratios for incidence of 1 or more MetSyn component over 4 ARIC visits 
among metabolically healthy individuals, according to BMI using linear spline coding with 
knots at 22.75, 25.0, 27.5, 30 kg/m2. The Atherosclerosis Risk in Communities (ARIC) 
Study, 1987–1998.
* Adjusted for age, sex, field center, race, alcohol use, smoking, education, physical activity.
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Table 1
Characteristics [n (%)] of 3,969 subjects included in the analysis, according to visit 1 body mass index 
(BMI).The Atherosclerosis Risk InCommunities (ARIC) Study, 1987–1998.
Body Mass Index (kg/m2) at visit 1
18.5–<25.0 25.0–<30.0 ≥30.0
N 2,062 1,449 458
Triglycerides (mg/dL)* 80.9 (26.5) 86.8 (27.1) 91.1 (26.4)
HDL-C (mg/dL)* 65.8 (16.0) 58.8 (14.0) 58.5 (11.9)
Systolic blood pressure (mmHg)* 108.2 (10.7) 111.5 (9.8) 114.2 (9.2)
Diastolic blood pressure (mmHg)* 67.1 (8.1) 69.7 (7.5) 71.2 (6.9)
Fasting Glucose (mg/dL)* 93.8 (7.1) 96.0 (6.7) 96.3 (6.9)
Waist circumference (cm)* 82.8 (7.6) 94.9 (7.1) 108.3 (11.1)
Age* 52.9 (5.6) 53.0 (5.6) 52.9 (5.6)
Female 1,417 (68.7) 736 (50.8) 298 (65.1)
African-American 271 (13.1) 307 (21.2) 148 (32.3)
Center
Forsyth County, NC 665 (32.3) 352 (24.3) 84 (18.3)
Jackson, MS 228 (11.1) 270 (18.6) 136 (30.0)
Suburban Minneapolis, MN 680 (32.9) 473 (32.6) 121 (26.4)
Washington County, MD 489 (23.7) 354 (24.4) 117 (25.6)
Education
Less than high school 263 (12.8) 256 (17.7) 99 (21.6)
High school 851 (41.3) 586 (40.4) 186 (40.6)
College 948 (46.0) 607 (41.9) 173 (37.8)
Smoking
Never 935 (45.3) 647 (44.7) 255 (55.7)
Former 600 (29.1) 525 (36.2) 138 (30.1)
Current 527 (25.6) 277 (19.1) 65 (14.2)
Alcohol use
Never/rare 843 (40.9) 561 (38.7) 236 (51.5)
Former 266 (12.9) 210 (14.5) 76 (16.6)
Light 231 (11.2) 173 (11.9) 44 (9.6)
Medium 361(17.5) 313(21.6) 57(12.5)
Heavy 359 (17.4) 192 (13.3) 45 (9.8)
Physical Activity(Baecke Index)
1st Tertile (0–2) 661 (32.1) 497 (34.4) 207 (45.4)
2nd Tertile (2–2.75) 642 (31.2) 439 (30.4) 128 (28.1)
3rd Tertile (2.75-) 758 (36.8) 510 (35.3) 121 (26.5)
Overweight at age 25 years (%) 97 (4.7) 325 (22.5) 212 (46.7)
*
Mean (standard deviation)
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Table 4
Associations of cross-classified BMI/waist circumference categorieson risk of developing MetSyn 
components. The Atherosclerosis Risk in Communities (ARIC) Study, 1987–1998.
Hazard Ratio* (95% Confidence Interval)
Elevated Triglycerides
BMI (kg/m2) Normal WC† Elevated WC†
18.5–<25.0 1. 1.13 (0.84, 1.54)
25.0–<30.0 1.45 (1.16, 1.80) 1.35 (1.09, 1.65)
≥30.0 1.18 (0.41, 3.38) 1.68 (1.30, 2.16)
p-interaction§ 0.48
Low HDL-C
Normal WC† Elevated WC†
18.5–<25.0 1. 1.10 (0.79, 1.51)
25.0–<30.0 1.49 (0.84, 1.65) 1.29 (1.06, 1.57)
≥30.0 0.57 (0.11, 2.97) 1.77 (1.39, 2.24)
p-interaction§ 0.03
High Blood Pressure
Normal WC† Elevated WC†
18.5–<25.0 1. 0.97 (0.74, 1.26)
25.0–<30.0 1.41 (1.18, 1.68) 1.02 (0.84, 1.24)
≥30.0 0.58 (0.15, 2.31) 1.57 (1.28, 1.93)
p-interaction§ 0.02
Elevated Glucose
Normal WC† Elevated WC†
18.5–<25.0 1. 1.01 (0.61, 1.67)
25.0–<30.0 1.71 (1.34, 2.19) 1.65 (1.27, 2.14)
≥30.0 0.76 (0.19, 2.99) 2.45 (1.86, 3.23)
p-interaction§ 0.08
*Adjusted for age, sex, field center, race, alcohol use, smoking, education, physical activity.
†
Elevated waist circumference (updated at each follow-up) defined as ≥102 cm among men or ≥88 cm among women.
§
P-value from likelihood ratio test for interaction between BMI and indicator of elevated waist circumference.
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